drugset / Trial / NCT06302140
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
RandomizedCrossoverOpen-labelBasic science
Summary
This study will determine how nanatinostat is absorbed, modified, and removed from the body (Part A), the amount of nanatinostat that becomes available to the body (Part B), and will evaluate the safety and tolerability of nanatinostat (Part C) in patients with advanced cancers.
Timeline
- Start
- 2024-02-28
- Primary completion
- 2025-01-15
- Completion
- 2025-01-15
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nanatinostat | Small molecule | 20 mg | Oral |
| Subject | Nanatinostat | Small molecule | 40 mg | Oral |
| Background | Valganciclovir | Small molecule | 900 mg | — |
Indications
No indication recorded.